Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza universal vaccine
- Development stage
- Approved
- Lead developer
- VaxThera
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The influenza universal vaccine is a viral vector-based prophylactic candidate being developed by VaxThera in collaboration with the University of Wisconsin. Unlike traditional seasonal flu vaccines that target the highly variable head of the hemagglutinin protein, this universal vaccine is designed to target conserved regions of the influenza virus. This strategy aims to provide broad and durable protection against a wide range of influenza A and B strains, including those with pandemic potential, potentially eliminating the requirement for annual vaccinations. The program is currently in the design and early development stage, leveraging viral vector technology to elicit robust immune responses.
- Other names
- Universal influenza vaccineVaxThera influenza universal vaccine
02
Targets
NP (Influenza B virus nucleoprotein)M2e (Influenza A matrix protein 2 ectodomain)NP (Influenza A virus nucleoprotein)
Beyond the preview
Go deeper on influenza universal vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza universal vaccine.